FDA批准用于治疗罕见良性软组织肿瘤的另一种选择
Another Option for Rare Benign Soft-Tissue Tumor Wins FDA Approval
FDA批准pimicotinib用于治疗具有高手术风险的不可切除的tenosynovial巨细胞瘤。该药在III期MANEUVER试验中显示54%的客观缓解率,主要副作用包括皮疹和疲劳。
详细描述了药物的适应症、疗效和不良反应,有助于了解其临床应用价值。
— Pimicotinib achieved 54% objective response rate in unresectable tenosynovial giant cell tumor
November 10, 2026 • 2 min read
The FDA approved the small-molecule inhibitor pimicotinib (Pimjetmi) for selected patients with symptomatic tenosynovial giant cell tumor (TGCT) and high surgical risk.
An oral selective inhibitor of colony stimulating factor-1 receptor (CSF-1R), pimicotinib is indicated for TGCT for which surgery might cause worsening functional limitation or severe morbidity. Pimicotinib is the third FDA-approved drug for TGCT, joining two other CSF-1R inhibitors, vimseltinib (Romvimza), approved in 2025, and pexidartinib (Turalio), approved in 2019.
TGCT is a rare, locally aggressive soft-tissue tumor that primarily affects otherwise healthy younger (median age 38) adults. The condition originates in the joint synovium, bursae, or tendon sheaths and has the potential to cause substantial functional limitation and morbidity. Surgery is the primary treatment when feasible.
Primary support for the approval came from the phase III MANEUVER trial. Investigators in Asia, Europe, and North America randomized 94 patients with unresectable TGCT 2:1 to pimicotinib or placebo. The trial met the primary endpoint of objective response rate (ORR) at week 25. The primary analysis showed an ORR of 54% with pimicotinib and 3% with placebo (P<0.0001).
Recently reported 2-year results from the trial showed durable responses with pimicotinib (76-78% at 2 years), along with improvements in pain, stiffness, and range of motion.
"For people living with TGCT, the impact of the disease is often felt through persistent limitations in mobility, physical function, and the ability to carry out everyday activities," investigator Vinod Ravi, MD, of the University of Texas MD Anderson Cancer Center in Houston, said last month in a press release from drugmaker EMD Serono announcing those results.
"What is encouraging about these 2-year findings is the consistency of improvements, not only in the durability of tumor response, but across the symptoms and functional outcomes that matter to patients," added Ravi. "Together with the observed safety profile, these results provide important insight into the potential for pimicotinib to deliver meaningful benefit over time."
According to the FDA, the most common adverse reactions in the pimicotinib arm (>20% of patients) were pruritus, rash, facial and periorbital edema, fatigue, nausea, headache, and peripheral edema. Laboratory abnormalities occurring in more than 30% of patients consisted of increased creatine phosphokinase, lactate dehydrogenase, aspartate aminotransferase, lipase, cholesterol, amylase, and alanine aminotransferase.
Pimicotinib was approved earlier this year in Canada and Switzerland and in China in 2025.
来源:MedPage Today · medpagetoday.com